Intensive first line FIr-C/FOx-C association of triplet chemotherapy plus cetuximab in RAS wild-type metastatic colorectal cancer patients: Preliminary phase II data and prediction of individual limiting toxicity syndromes by pharmacogenomic biomarkers.

被引：0
|
作者：
Bruera, Gemma
Massacese, Silvia
Pepe, Francesco
Malapelle, Umberto
Dal Mas, Antonella
Ciacco, Eugenio
Calvisi, Giuseppe
Marchetti, Paolo
Troncone, Giancarlo
Simmaco, Maurizio
Ricevuto, Enrico
机构：
[1] Univ Aquila, S Salvatore Hosp, Dept Biotechnol & Appl Clin Sci, Oncol Territorial Care,Oncol Network ASL1 Abruzzo, Laquila, Italy
[2] S Salvatore Hosp, Pharm Unit, Oncol Network ASL1 Abruzzo, Laquila, Italy
[3] Univ Federico II, Dept Publ Hlth, Naples, Italy
[4] S Salvatore Hosp, Oncol Network ASL1 Abruzzo, Pathol, Laquila, Italy
[5] Sapienza Univ Rome, S Andrea Hosp, Rome, Italy
[6] S Andrea Hosp, Adv Mol Diagnost, Rome, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.e15517
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e15517
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Intensive first line FIr-C/FOx-C association of triplet chemotherapy plus cetuximab in RAS wild-type metastatic colorectal cancer patients: Preliminary phase II data and individual limiting toxicity syndromes prediction by pharmacogenomic biomarkers
    Bruera, G.
    Massacese, S.
    Pepe, F.
    Malapelle, U.
    Dal Mas, A.
    Ciacco, E.
    Calvisi, G.
    Marchetti, P.
    Troncone, G.
    Simmaco, M.
    Ricevuto, E.
    ANNALS OF ONCOLOGY, 2018, 29
  • [2] Intensive first-line triplet chemotherapy plus cetuximab FIr-C/FOx-C in RAS wild-type MCRC: Preliminary phase II data and prediction of individual limiting toxicity syndromes by pharmacogenomic biomarkers.
    Bruera, Gemma
    Massacese, Silvia
    Dal Mas, Antonella
    Ficorella, Corrado
    Ciacco, Eugenio
    Calvisi, Giuseppe
    Simmaco, Maurizio
    Ricevuto, Enrico
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [3] Intensive first-line FIr-C/FOx-C association of triplet chemotherapy plus cetuximab in RAS wild-type metastatic colorectal cancer patients: preliminary phase II data and prediction of individual limiting toxicity syndromes by pharmacogenomic biomarkers
    Bruera, Gemma
    Massacese, Silvia
    Pepe, Francesco
    Malapette, Umberto
    Mas, Antonella Dat
    Ciacco, Eugenio
    Calvisi, Giuseppe
    Troncone, Giancarlo
    Simmaco, Maurizio
    Ricevuto, Enrico
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2019, 11
  • [4] Predictive wild-type RAS/BRAF and pharmacogenetic biomarkers drive selection of metastatic colorectal cancer patients fit for intensive first-line FIr-C/FOx-C schedule adding cetuximab to triplet chemotherapy
    Russell, Mike
    Lowenstein, Cassandra L.
    Zhang, Xuqing
    Roach, Jeremy
    Song, Jianing
    Nagilla, Rakesh
    Orth, Peter
    Tudor, Matt
    Deng, Qiaolin
    Sui, Zhihua
    Strickland, Corey
    Jolivette, Larry J.
    Priestley, E. Scott
    Mohammad, Helai P.
    MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)
  • [5] Triplet chemotherapy plus cetuximab as first-line treatment in extended RAS wild-type metastatic colorectal cancer patients
    Samalin, Emmanuelle
    Mazard, Thibault
    Assenat, Eric
    Rouyer, Magali
    de la Fouchardiere, Christelle
    Guimbaud, Rosine
    Smith, Denis
    Portales, Fabienne
    Ychou, Marc
    Adenis, Antoine
    Fiess, Catherine
    Lopez-Crapez, Evelyne
    Thezenas, Simon
    DIGESTIVE AND LIVER DISEASE, 2024, 56 (08) : 1375 - 1381
  • [6] Quality of Life Analysis in Patients With RAS Wild-Type Metastatic Colorectal Cancer Treated With First-Line Cetuximab Plus Chemotherapy
    Yamaguchi, Kensei
    Ando, Masahiko
    Ooki, Akira
    Beier, Frank
    Guenther, Silke
    von Hohnhorst, Philipp
    Van Cutsem, Eric
    CLINICAL COLORECTAL CANCER, 2017, 16 (02) : E29 - E37
  • [7] The impact of toxicity and efficacy on quality of life in KRAS wild-type metastatic colorectal cancer patients treated with first-line chemotherapy plus cetuximab
    Yamaguchi, K.
    Ando, M.
    Ooki, A.
    Beier, F.
    Von Hohnhorst, P.
    Esser, R.
    Van Cutsem, E.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S518 - S518
  • [8] A triplet combination of FOLFOXIRI plus cetuximab as first-line treatment in RAS wild-type, metastatic colorectal cancer: a dose-escalation phase Ib study
    Kadowaki, Shigenori
    Masuishi, Toshiki
    Ura, Takashi
    Sugiyama, Keiji
    Mitani, Seiichiro
    Narita, Yukiya
    Taniguchi, Hiroya
    Muro, Kei
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2021, 26 (04) : 701 - 707
  • [9] A triplet combination of FOLFOXIRI plus cetuximab as first-line treatment in RAS wild-type, metastatic colorectal cancer: a dose-escalation phase Ib study
    Shigenori Kadowaki
    Toshiki Masuishi
    Takashi Ura
    Keiji Sugiyama
    Seiichiro Mitani
    Yukiya Narita
    Hiroya Taniguchi
    Kei Muro
    International Journal of Clinical Oncology, 2021, 26 : 701 - 707
  • [10] Amphiregulin can predict treatment resistance to palliative first-line cetuximab plus FOLFIRI chemotherapy in patients with RAS wild-type metastatic colorectal cancer
    Sang-A Kim
    Hyejoo Park
    Kui-Jin Kim
    Ji-Won Kim
    Ji Hea Sung
    Milang Nam
    Ju Hyun Lee
    Eun Hee Jung
    Koung Jin Suh
    Ji Yun Lee
    Se Hyun Kim
    Jeong-Ok Lee
    Jin Won Kim
    Yu Jung Kim
    Jee Hyun Kim
    Soo-Mee Bang
    Jong Seok Lee
    Keun-Wook Lee
    Scientific Reports, 11
12345